These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1070 related articles for article (PubMed ID: 31733195)

  • 1. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
    Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
    Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance, polycystic ovary syndrome and metformin.
    Pugeat M; Ducluzeau PH
    Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostics of polycystic ovary syndrome].
    Lazúrová I; Figurová J; Lazúrová Z
    Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S40-4. PubMed ID: 27124971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).
    Siddiqui S; Mateen S; Ahmad R; Moin S
    J Assist Reprod Genet; 2022 Nov; 39(11):2439-2473. PubMed ID: 36190593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
    González F
    Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
    Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
    Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
    Indran IR; Lee BH; Yong EL
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():12-24. PubMed ID: 27118251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Insulin resistance and polycystic ovary syndrome].
    Bernard L; Christin-Maître S; Basille C; Chabbert-Buffet N
    Gynecol Obstet Fertil; 2003 Feb; 31(2):109-16. PubMed ID: 12718982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic, hormonal and metabolic aspects of PCOS: an update.
    De Leo V; Musacchio MC; Cappelli V; Massaro MG; Morgante G; Petraglia F
    Reprod Biol Endocrinol; 2016 Jul; 14(1):38. PubMed ID: 27423183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.
    Singh P; Agress A; Madrigal VK; Magyar C; Ostrzega N; Chazenbalk GD; Dumesic DA
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2796-2800. PubMed ID: 30759233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.